[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
November 21, 2012

Effective Treatment of Traumatic Brain InjuryLearning From Experience

Author Affiliations

Author Affiliations: Neurology and Polytrauma Services and Department of Neurology, Cleveland VA Medical Center (Drs Ruff and Riechers) and Department of Neurosciences (Dr Ruff), Case Western Reserve University, Cleveland, Ohio.

JAMA. 2012;308(19):2032-2033. doi:10.1001/jama.2012.14008

In this issue of JAMA, Zafonte and colleagues1 present the findings of the Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind study comparing citicoline vs placebo. In this trial, 1213 study participants with complicated mild, moderate, or severe traumatic brain injury (TBI) were randomized to receive 2000 mg of citicoline or placebo daily for 90 days. The study, which did not demonstrate any benefits of citicholine treatment, is likely to have implications not only for the use of citicoline in patients with TBI but also for the design of future trials of TBI therapies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×